ClinicalTrials.gg
CompletedNCT04842643Updated Jan 20, 2025Results posted

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

A Phase 3 interventional study of IGSC 20% infusion in Primary Immunodeficiency Disease, sponsored by Takeda. Completed at 8 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
16th of 18
12 · median 47
Started
2021
the only one that year
Phase 3
9 of 23
none open now
Registered
15th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 9 in phase 3, and was the 15th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study.

The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

03

Conditions studied

  • Primary Immunodeficiency Disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has completed or is about to complete Takeda Clinical Study TAK-664-3001.

    A participant is considered to have completed Study TAK-664-3001 successfully if they fulfill the following criterion: Completed Epoch 2, in which IGSC, 20% is administered weekly (completion of Epoch 3, in which IGSC, 20% is administered biweekly, is not mandatory for participation in TAK-664-3002 study).

  2. Written is obtained from either the Participant or the Participant's legally authorized representative prior to any study-related procedures and study product administration.
  3. Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant has developed a new serious medical condition during participation in Study TAK-664-3001 such that the Participant's safety or medical care would be impacted by participation in the extension study TAK-664-3002.
  2. Participant is scheduled to participate in another non-Takeda clinical study involving an Product or device-used-in-clinical-trial in the course of this study.
  3. If a female of , Participant is pregnant or has a negative pregnancy test but does not agree to employ adequate measures for the duration of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    IGSC, 20%

    Participants who completed Epoch 2 of core study TAK-664-3001 (NCT04346108), received between 50 to 200 mg/kg of Immune globulin subcutaneous (IGSC) infusion, 20% infusion once a week (Epoch 2 regimen) and 100 to 400 mg/kg of IGSC infusion, 20% biweekly (Epoch 3 regimen) until the study drug becomes commercially available.

    Biological: IGSC 20% infusion

Interventions

  • IGSC 20% infusion,

    Also known as: Immune Globulin Infusion (Human)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

    TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

  2. Number of Participants With Drug-related and Non-related TEAEs

    TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). Any TEAE that was recorded by the investigator as "probably related" or "possibly related" to study drug was considered as study drug related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE.

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

  3. Number of Participants With Severe, Local and Systemic TEAEs

    A severe TEAE was an AE that caused considerable interference with the participant's usual activities. Local TEAEs were defined as AEs that were included in the MedDRA Higher Level Group Term "administration site reactions" or contained the phrase "injection site" or "infusion site". Systemic TEAEs were defined as AEs that were not included in the Medical Dictionary for Regulatory Activities (MedDRA) Higher Level Group Term "administration site reactions" and did not contain the phrase "injection site" or "infusion site".

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

  4. Number of Participants With TEAEs Leading to Premature Discontinuation From Study and Infusion-associated TEAEs

    Infusion associated TEAEs were defined as any TEAE that began during study drug infusion or within 72 hours of completion of study drug infusion. TEAEs leading to premature discontinuation from study and infusion-associated TEAEs were reported.

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

Secondary outcomes

  1. Serum Trough Levels of Total Immune Globulin G (IgG) and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Weekly Administration of IGSC, 20%

    Serum trough levels of total IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.

    Time frame: At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)

  2. Serum Trough Levels of IgG and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Biweekly Administration of IGSC, 20%

    Serum trough levels of IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.

    Time frame: At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)

  3. Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)

    The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  4. Annual Rate of All Infections

    The annual rate of infections was calculated as the mean number of infections per participant per year. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  5. Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection

    Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  6. Number of Days Participants on Antibiotics

    Number of days on antibiotics was defined as the number of days those antibiotics were taken as concomitant medications and was standardized to per year (365.25 days). Number of days participants on antibiotics were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  7. Number of Hospitalizations Due to Illness or Infection

    Number of hospitalizations were standardized to per year (365.25 days). Hospitalizations were measured by asking participants to report the number of nights they have stayed overnight in the hospital during the year, for something related to their own health. Number of hospitalizations due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  8. Length of Hospital Stay Due to Illness or Infection

    Length of hospital stay per stay was standardized to per year (365.25 days). Number of days due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  9. Number of Acute Physician Visits Due to Illness/Infection

    Number of acute physician visits is standardized to per year (365.25 days). Number of acute (urgent or unscheduled) physician visits due to illness/infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

    Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)

  10. Number of Participants With Their Response for Treatment Preference Questionnaire

    Treatment preference questionnaire is a self-administered questionnaire developed to assess participant's preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. For First question "Before participation in the trial(s), where did you receive your immunoglobulin therapy" participants were allowed to select multiple answers for options ("At the hospital"; "At home"; "Other") for their treatment. As a result, the sum of responders in the arm "IGSC, 20%: \>=14 Years" for the first question were higher than the total number of participants analyzed in the category.

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

  11. Number of Participants With Tolerability Events Related to the Infusion of Study Drug

    An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to a TEAE related to study drug infusion. A tolerability event was considered to have occurred if an infusion was not tolerable.

    Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose

07

Results

Posted Jan 20, 2025

Participant flow

Participants took part in the study at 8 investigative sites in Japan from 27 April 2021 to 25 April 2024.

Participant flow — Overall Study
MilestoneIGSC, 20%
Started12
Completed10
Not completed2
Withdrew: Physician decision1
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
ParticipantsIGSC, 20%
TEAEs12
Serious TEAEs3
Non-serious TEAEs12
PrimaryNumber of Participants With Drug-related and Non-related TEAEs

TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). Any TEAE that was recorded by the investigator as "probably related" or "possibly related" to study drug was considered as study drug related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE.

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With Drug-related and Non-related TEAEs
ParticipantsIGSC, 20%
Drug-related TEAEs9
Non-related TEAEs12
PrimaryNumber of Participants With Severe, Local and Systemic TEAEs

A severe TEAE was an AE that caused considerable interference with the participant's usual activities. Local TEAEs were defined as AEs that were included in the MedDRA Higher Level Group Term "administration site reactions" or contained the phrase "injection site" or "infusion site". Systemic TEAEs were defined as AEs that were not included in the Medical Dictionary for Regulatory Activities (MedDRA) Higher Level Group Term "administration site reactions" and did not contain the phrase "injection site" or "infusion site".

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With Severe, Local and Systemic TEAEs
ParticipantsIGSC, 20%
Severe TEAEs3
Local TEAEs8
Systemic TEAEs12
PrimaryNumber of Participants With TEAEs Leading to Premature Discontinuation From Study and Infusion-associated TEAEs

Infusion associated TEAEs were defined as any TEAE that began during study drug infusion or within 72 hours of completion of study drug infusion. TEAEs leading to premature discontinuation from study and infusion-associated TEAEs were reported.

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Premature Discontinuation From Study and Infusion-associated TEAEs
ParticipantsIGSC, 20%
TEAEs Leading to Premature Discontinuation0
Infusion-associated TEAEs12
SecondarySerum Trough Levels of Total Immune Globulin G (IgG) and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Weekly Administration of IGSC, 20%

Serum trough levels of total IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.

Time frame:
At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)
Reported as:
Geometric mean · grams per liter (g/L)
Serum Trough Levels of Total Immune Globulin G (IgG) and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Weekly Administration of IGSC, 20%
grams per liter (g/L)IGSC, 20%
IgG 16.14 (4.25 to 8.87)
IgG 23.52 (2.35 to 5.28)
IgG 3NA (NA to NA)
IgG 40.305 (0.165 to 0.567)
IgG Total11.0 (7.29 to 16.5)
SecondarySerum Trough Levels of IgG and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Biweekly Administration of IGSC, 20%

Serum trough levels of IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.

Time frame:
At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)
Reported as:
Geometric mean · g/L
Serum Trough Levels of IgG and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Biweekly Administration of IGSC, 20%
g/LIGSC, 20%
IgG 15.36 (4.55 to 6.33)
IgG 23.42 (3.03 to 3.86)
IgG 3NA (NA to NA)
IgG 40.250 (0.219 to 0.284)
IgG Total8.98 (7.78 to 10.4)
SecondaryAnnual Rate of Validated Acute Serious Bacterial Infections (ASBI)

The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Mean · infections per year
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)
infections per yearIGSC, 20%
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)0.00 ± 0.000
SecondaryAnnual Rate of All Infections

The annual rate of infections was calculated as the mean number of infections per participant per year. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Mean · infections per year
Annual Rate of All Infections
infections per yearIGSC, 20%
Annual Rate of All Infections1.42 ± 1.119
SecondaryNumber of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection

Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Median · days
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection
daysIGSC, 20%
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection1.91 (0.0 to 31.9)
SecondaryNumber of Days Participants on Antibiotics

Number of days on antibiotics was defined as the number of days those antibiotics were taken as concomitant medications and was standardized to per year (365.25 days). Number of days participants on antibiotics were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Median · days
Number of Days Participants on Antibiotics
daysIGSC, 20%
Number of Days Participants on Antibiotics2.55 (0.0 to 57.8)
SecondaryNumber of Hospitalizations Due to Illness or Infection

Number of hospitalizations were standardized to per year (365.25 days). Hospitalizations were measured by asking participants to report the number of nights they have stayed overnight in the hospital during the year, for something related to their own health. Number of hospitalizations due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Mean · hospitalization
Number of Hospitalizations Due to Illness or Infection
hospitalizationIGSC, 20%
Number of Hospitalizations Due to Illness or Infection0.21 ± 0.370
SecondaryLength of Hospital Stay Due to Illness or Infection

Length of hospital stay per stay was standardized to per year (365.25 days). Number of days due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Median · days
Length of Hospital Stay Due to Illness or Infection
daysIGSC, 20%
Length of Hospital Stay Due to Illness or Infection0.00 (0.0 to 3.9)
SecondaryNumber of Acute Physician Visits Due to Illness/Infection

Number of acute physician visits is standardized to per year (365.25 days). Number of acute (urgent or unscheduled) physician visits due to illness/infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.

Time frame:
From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Reported as:
Mean · visits per year
Number of Acute Physician Visits Due to Illness/Infection
visits per yearIGSC, 20%
Number of Acute Physician Visits Due to Illness/Infection2.66 ± 2.652
SecondaryNumber of Participants With Their Response for Treatment Preference Questionnaire

Treatment preference questionnaire is a self-administered questionnaire developed to assess participant's preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. For First question "Before participation in the trial(s), where did you receive your immunoglobulin therapy" participants were allowed to select multiple answers for options ("At the hospital"; "At home"; "Other") for their treatment. As a result, the sum of responders in the arm "IGSC, 20%: \>=14 Years" for the first question were higher than the total number of participants analyzed in the category.

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With Their Response for Treatment Preference Questionnaire
ParticipantsIGSC, 20%: 2-13 YearsIGSC, 20%: >=14 Years
Before participation in the trial(s), where did you receive your immunoglobulin therapy: At home00
Before participation in trial(s), where did you receive your immunoglobulin therapy: At hospital38
Before participation in the trial(s), where did you receive your immunoglobulin therapy: Other04
Where do you Prefer to Receive Your Immunoglobulin Therapy: At Hospital11
Where do you Prefer to Receive Your Immunoglobulin Therapy: At Home06
Where do you Prefer to Receive Your Immunoglobulin Therapy: No Preference22
The Frequency of Administration: Like very much11
The Frequency of Administration: Like14
The Frequency of Administration: No preference13
The Frequency of Administration: Dislike01
The Frequency of Administration: Dislike very much00
The number of needlesticks per month: Like very much11
The number of needlesticks per month: Like15
The number of needlesticks per month: No preference12
The number of needlesticks per month: Dislike01
The number of needlesticks per month: Dislike very much00
Total time spent for treatment per month: Like very much03
Total time spent for treatment per month: Like12
Total time spent for treatment per month: No preference11
Total time spent for treatment per month: Dislike13
Total time spent for treatment per month: Dislike very much00
The ease of administration: Like very much13
The ease of administration: Like24
The ease of administration: No preference01
The ease of administration: Dislike01
The ease of administration: Dislike very much00
The potential to self-administer: Like very much25
The potential to self-administer: Like04
The potential to self-administer: No preference00
The potential to self-administer: Dislike00
The potential to self-administer: Dislike very much10
Ability to fit treatment into schedule: Like very much15
Ability to fit treatment into schedule: Like21
Ability to fit treatment into schedule: No preference03
Ability to fit treatment into schedule: Dislike00
Ability to fit treatment into schedule: Dislike very much00
The overall convenience: Like very much04
The overall convenience: Like33
The overall convenience: No preference02
The overall convenience: Dislike00
The overall convenience: Dislike very much00
The amount of time administration takes: Like very much01
The amount of time administration takes: Like15
The amount of time administration takes: No preference11
The amount of time administration takes: Dislike12
The amount of time administration takes: Dislike very much00
Complexity of administration: Like very much02
Complexity of administration process: Like34
Complexity of administration: No preference02
Complexity of administration: Dislike01
Complexity of administration: Dislike very much00
Ability to self-administer: Like very much26
Ability to self-administer: Like13
Ability to self-administer: No preference00
Ability to self-administer: Dislike very much00
Ability to self-administer: Dislike00
Choose to continue receiving IGSC: Yes37
Choose to continue receiving IGSC: No02
Factor influence decision: Two way needle, to see more variation in volume of chemical solution.01
Factor influenced decision: Can be self-administered at home10
Factor influenced decision: Easy administration method, easy to use01
Factor influenced decision: Feel relieved01
Factor influenced decision: Fewer side effects. IgG levels stabilized and became easier01
Factor influence decision:.Take time to prepare, clean up, for area affected by needle to recover.01
Factor influenced decision: Less susceptible to infections. Atopic dermatitis improved10
Factor influenced decision: No answer10
Factor influenced decision: No more coughing01
Factor influenced decision: The values are stable01
Factor influenced decision: Time is short01
Factor influence decision: There were no major side effects and stable medical condition01
SecondaryNumber of Participants With Tolerability Events Related to the Infusion of Study Drug

An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to a TEAE related to study drug infusion. A tolerability event was considered to have occurred if an infusion was not tolerable.

Time frame:
From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Reported as:
Count of participants · Participants
Number of Participants With Tolerability Events Related to the Infusion of Study Drug
ParticipantsIGSC, 20%
Infusion rate was reduced1
Infusion was interrupted4
Infusion was stopped1

Adverse events

Collected over From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGSC, 20%0/12 (0%)3/12 (25%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventIGSC, 20%
Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/12
Diabetic ketoacidosisMetabolism and nutrition disorders1/12
Rhegmatogenous retinal detachmentEye disorders1/12
Most frequent other events
Showing 10 of 113
Most frequent other events
EventIGSC, 20%
HeadacheNervous system disorders6/12
COVID-19Infections and infestations5/12
PyrexiaGeneral disorders5/12
Vaccination complicationInjury, poisoning and procedural complications5/12
Injection site swellingGeneral disorders4/12
SinusitisInfections and infestations4/12
Dental cariesGastrointestinal disorders3/12
GastroenteritisInfections and infestations3/12
Injection site erythemaGeneral disorders3/12
Injection site painGeneral disorders3/12

Baseline characteristics

All-Treated Set consisted of all enrolled participants who received IGSC, 20% administration at least once in this study.

Age, Continuous
Age, Continuous(years)IGSC, 20%
Mean36.0 ± 21.68
Sex: Female, Male
Sex: Female, Male(Participants)IGSC, 20%
Female7
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IGSC, 20%
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGSC, 20%
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Nagoya University Hospital
    Nagoya, Aichi, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, Japan
  • Kanazawa University Hospital
    Kanazawa, Ishikawa, Japan
  • National defense medical college Hospital
    Tokorozawa, Saitama, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Gifu University Hospital
    Gifu, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Tokyo Medical Dental University Hospital
    Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Apr 2024, 35 months.

Results were first posted in Jan 2025, 8 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2021
First posted
Apr 13, 2021
StartActual
Apr 27, 2021
Primary completionActual
Apr 25, 2024
CompletionActual
Apr 25, 2024
Results first posted
Jan 20, 2025
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04842643
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 13, 2021
Start date
Apr 27, 2021
Primary completion
Apr 25, 2024
Completion
Apr 25, 2024
Results posted
Jan 20, 2025
Last update
Jan 20, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion